Ron Squarer, Chief Executive of Array BioPharma (NASDAQ: ARRY), sits down with biotech stock analyst David Moskowitz to discuss the company`s pipeline, positioning, and commercialization strategies.
Squarer says robust partnerships are representative of the quality of Array`s science; the company has 14 compounds under development with 10 in Phase II studies. He goes on to talk about moving three products into late-stage trials and the importance of strategic partners in AstraZeneca (AZN), Novartis (NVS), Roche (RHHBY) and Amgen (AMGN).
Array plans on partnering more of its products according to Squarer, who says the company has historically been able to negotiate deals with large upfront, milestone, and royalty payments. Array BioPharma`s Chief Executive also provides insight into some of the catalysts for this year and some moving forward.
Array BioPharma's proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes several small molecule drug candidates that are designed to regulate targets in therapeutically important biologic pathways. Its discovery platform includes: structural biology, predictive informatics, high throughput screening, cell biology, lead generation, lead optimization, drug metabolism, pharmacology, process research & cGMP and clinical or regulatory technologies.
Array BioPharma's product pipeline includes: ARRY-162, an orally active MEK inhibitor that has demonstrated potent anti-inflammatory and bone-protective activity along with synergistic efficacy indicated for the treatment of rheumatoid arthritis; ARRY-797, a selective, orally active inhibitor of p38 (Pan-cytokine) indicated for the treatment of cancer; ARRY-614, a potent, orally active inhibitor of p38, Abl, Tie2 and VEGFR2 indicated for the treatment of arthritis; ARRY-543, a novel, oral, pan-ErbB inhibitor indicated for the treatment of cancer etc.
Array BioPharma has alliances with Amgen Inc, AstraZeneca Plc, Celgene Corporation, Genentech, Inc, Horizon Discovery Ltd, Japan Tobacco Inc, Ono Pharmaceutical Co., Ltd. and others.
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites